Chiron Vaccines, the world's fifth largest vaccine business, and Panacea Biotec Ltd, India have stepped into a new strategic alliance today. The new joint venture company, Chiron Panacea Vaccines, will focus on providing new breakthrough vaccines in India.
John Lambert, president, Chiron Vaccines along with Rajesh Jain, joint managing director, Panacea Biotec unveiled the future plans for this joint venture. This strategic alliance will provide India with a key competitive advantage in providing new generation combination vaccines to help prevent life threatening infectious disease, said in a release.
The Company, with its partner Chiron Vaccines, is the first Company to develop the breakthrough fully liquid Pentavalent combination vaccine, which will protect against five potentially life threatening infectious diseases: Diphtheria, Tetanus, Whooping cough, Hepatitis B and H, influenzae type b. which is a major causative bacteria for pneumonia and meningitis.
Rajesh Jain Jt, MD, Panacea Biotec comments: "In the last two decades, Indian Companies have made significant progress in providing much needed health solutions to the people of India and their role is being recognized in various international markets as well."
"We are delighted that Panacea Biotec is taking a world leading role by forming this joint ventures with Chiron Vaccines to market highly advanced technology driven vaccines," he added.